<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id>
      <journal-id journal-id-type="iso-abbrev">Emerging Infect. Dis</journal-id>
      <journal-id journal-id-type="publisher-id">EID</journal-id>
      <journal-title-group>
        <journal-title>Emerging Infectious Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1080-6040</issn>
      <issn pub-type="epub">1080-6059</issn>
      <publisher>
        <publisher-name>Centers for Disease Control and Prevention</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">15714664</article-id>
      <article-id pub-id-type="pmc">3294367</article-id>
      <article-id pub-id-type="publisher-id">04-0145</article-id>
      <article-id pub-id-type="doi">10.3201/eid1101.040145</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letters to the Editor</subject>
        </subj-group>
        <subj-group subj-group-type="article-type">
          <subject>Letter</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Fluoroquinolone-resistant <italic>Salmonella</italic> Paratyphi A</article-title>
        <alt-title alt-title-type="running-head">Fluoroquinolone-resistant Salmonella Paratyphi A</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Adachi</surname>
            <given-names>Takuya</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sagara</surname>
            <given-names>Hiroko</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hirose</surname>
            <given-names>Kenji</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">&#x2020;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Watanabe</surname>
            <given-names>Haruo</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">&#x2020;</xref>
        </contrib>
        <aff id="aff1"><label>*</label>Yokohama Municipal Citizen&#x2019;s Hospital, Yokohama, Japan</aff>
        <aff id="aff2"><label>&#x2020;</label>National Institute of Infectious Diseases, Tokyo, Japan</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Address for correspondence: Takuya Adachi, 56 Okazawacho, Hodogaya-Ku, Yokohama 240-8555, Japan; fax: +81-45-331-1960; email: <email xlink:href="t-adachi@bd5.so-net.ne.jp">t-adachi@bd5.so-net.ne.jp</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2005</year>
      </pub-date>
      <volume>11</volume>
      <issue>1</issue>
      <fpage>172</fpage>
      <lpage>174</lpage>
      <kwd-group kwd-group-type="author">
        <title>Keywords: </title>
        <kwd>letter</kwd>
        <kwd>Salmonella paratyphi A</kwd>
        <kwd>carrier state</kwd>
        <kwd>drug resistance</kwd>
        <kwd>fluoroquinolones</kwd>
        <kwd>point mutation</kwd>
        <kwd>DNA gyrase</kwd>
        <kwd>DNA topoisomerase IV</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p><bold>To the Editor</bold>: Fluoroquinolones have been the drug of choice for treating typhoid and paratyphoid fever since the beginning of the 1990s. Multidrug-resistant strains began to prevail in disease-endemic areas, and former first-line antimicrobial drugs, such as chloramphenicol, were sometimes ineffective (<xref ref-type="bibr" rid="R1"><italic>1</italic></xref>). In recent years, however, strains with decreased susceptibility to quinolones have emerged, and clinical treatment failure is a serious concern (<xref ref-type="bibr" rid="R2"><italic>2</italic></xref>&#x2013;<xref ref-type="bibr" rid="R5"><italic>5</italic></xref>).</p>
    <p>An 87-year-old woman was referred from a local clinic to Yokohama Municipal Citizen&#x2019;s Hospital in July 2002 because <italic>Salmonella enterica</italic> serovar Paratyphi A was detected in her urine. She had no subjective symptoms such as pain on urination or urinary urgency, and her temperature was normal. She had never had paratyphoid fever, and she had not traveled abroad. No other person in the community had paratyphoid. Before being admitted to the hospital, she had experienced frequent episodes of urinary tract infection and had been empirically treated each time with oral antimicrobial drugs, including ciprofloxacin. She had been given a dose of 600 mg/day for 7 days, 25 times in the last 4 years.</p>
    <p>The patient did not display any abnormal findings on physical examination. <italic>S</italic>. Paratyphi A was not detected in the urine but was confirmed in the stool; therefore, the previous report of bacteriuria could have been due to contamination of a urine sample with feces. An ultrasound showed a polyp and multiple stones in her gallbladder. A carrier state was suspected. Bile was obtained by duodenal aspiration and was positive for <italic>S</italic>. Paratyphi A. The patient was considered to be an asymptomatic cholecystic carrier of <italic>S</italic>. Paratyphi A.</p>
    <p>On disk diffusion susceptibility testing, the isolate was resistant to nalidixic acid (NA) and to ofloxacin. The MIC of ofloxacin was as high as 256 &#xB5;g/mL, and the MIC of ciprofloxacin was128 &#xB5;g/mL (<xref ref-type="table" rid="T1">Table</xref>). An open cholecystectomy was performed for treatment of the polyp, the stones, and the highly quinolone-resistant bacteria. A routine perioperative intravenous antimicrobial agent, cefmetazole, was administered as surgical prophylaxis. The polyp was malignant, and the operation was curative. The patient resumed normal activities, and had no further fecal excretion of <italic>S</italic>. Paratyphi A.</p>
    <table-wrap id="T1" position="float">
      <label>Table</label>
      <caption>
        <title>MICs of antimicrobial agents for the isolate of <italic>Salmonella enterica</italic> serovar Paratyphi A*</title>
      </caption>
      <table frame="hsides" rules="groups">
        <col width="130" span="1"/>
        <col width="92" span="1"/>
        <col width="95" span="1"/>
        <thead>
          <tr>
            <th valign="top" align="left" scope="col" rowspan="1" colspan="1">&#xA0;</th>
            <th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">MIC (&#xB5;g/mL)<hr/></th>
          </tr>
          <tr>
            <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Antimicrobial agent</th>
            <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Etest</th>
            <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Broth microdilution</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ampicillin</td>
            <td valign="top" align="center" rowspan="1" colspan="1">4</td>
            <td valign="top" align="center" rowspan="1" colspan="1">ND</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Chloramphenicol</td>
            <td valign="top" align="center" rowspan="1" colspan="1">16</td>
            <td valign="top" align="center" rowspan="1" colspan="1">ND</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Gentamicin</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.06</td>
            <td valign="top" align="center" rowspan="1" colspan="1">ND</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Kanamycin</td>
            <td valign="top" align="center" rowspan="1" colspan="1">1</td>
            <td valign="top" align="center" rowspan="1" colspan="1">ND</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Streptomycin</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.75</td>
            <td valign="top" align="center" rowspan="1" colspan="1">ND</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sulfamethoxazole/trimethoprim</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.5</td>
            <td valign="top" align="center" rowspan="1" colspan="1">ND</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Tetracycline</td>
            <td valign="top" align="center" rowspan="1" colspan="1">8</td>
            <td valign="top" align="center" rowspan="1" colspan="1">ND</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cefoperazon</td>
            <td valign="top" align="center" rowspan="1" colspan="1">1.5</td>
            <td valign="top" align="center" rowspan="1" colspan="1">ND</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cefotaxime</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.38</td>
            <td valign="top" align="center" rowspan="1" colspan="1">ND</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ceftriaxone</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.19</td>
            <td valign="top" align="center" rowspan="1" colspan="1">ND</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Imipenem</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.19</td>
            <td valign="top" align="center" rowspan="1" colspan="1">ND</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Aztreonam</td>
            <td valign="top" align="center" rowspan="1" colspan="1">0.125</td>
            <td valign="top" align="center" rowspan="1" colspan="1">ND</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Fosfomycin</td>
            <td valign="top" align="center" rowspan="1" colspan="1">64</td>
            <td valign="top" align="center" rowspan="1" colspan="1">ND</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Nalidixic acid</td>
            <td valign="top" align="center" rowspan="1" colspan="1">&gt;256</td>
            <td valign="top" align="center" rowspan="1" colspan="1">ND</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Norfloxacin</td>
            <td valign="top" align="center" rowspan="1" colspan="1">&gt;256</td>
            <td valign="top" align="center" rowspan="1" colspan="1">1024</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ofloxacin</td>
            <td valign="top" align="center" rowspan="1" colspan="1">&gt;32</td>
            <td valign="top" align="center" rowspan="1" colspan="1">256</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sparfloxacin</td>
            <td valign="top" align="center" rowspan="1" colspan="1">&gt;32</td>
            <td valign="top" align="center" rowspan="1" colspan="1">256</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ciprofloxacin</td>
            <td valign="top" align="center" rowspan="1" colspan="1">&gt;32</td>
            <td valign="top" align="center" rowspan="1" colspan="1">128</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Levofloxacin</td>
            <td valign="top" align="center" rowspan="1" colspan="1">ND</td>
            <td valign="top" align="center" rowspan="1" colspan="1">128</td>
          </tr>
          <tr>
            <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Tosufloxacin</td>
            <td valign="top" align="center" rowspan="1" colspan="1">ND</td>
            <td valign="top" align="center" rowspan="1" colspan="1">128</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <p>*ND, no data.</p>
      </table-wrap-foot>
    </table-wrap>
    <p>Polymerase chain reaction (PCR) amplification and DNA sequencing were conducted to detect mutations responsible for the fluoroquinolone resistance. Nucleotide sequences of <italic>gyrA</italic>, <italic>gyrB</italic>, <italic>parC</italic>, and <italic>parE</italic> genes were investigated. The primers used for PCR amplification and DNA sequencing have been previously described (<xref ref-type="bibr" rid="R6"><italic>6</italic></xref>,<xref ref-type="bibr" rid="R7"><italic>7</italic></xref>). An ABI Prism dye terminator cycle sequencing kit (Perkin-Elmer, Applied Biosystems, Foster City, CA) and an automated sequencer (311A; Perkin-Elmer, Applied Biosystems) were used. The isolated strain possessed triple point mutations. The first 2 mutations were in the <italic>gyrA</italic> gene, which encodes DNA gyrase, at codon 83 (TCC to TTC), which substitutes phenylalanine for serine, and at codon 87 (GAC to AAC), which substitutes asparagine for aspartic acid. The third mutation was in the <italic>parC</italic> gene, which encodes DNA topoisomerase IV, at codon 84 (GAA to AAA), which substitutes lysine for glutamic acid. No mutations were found in <italic>gyrB</italic> and <italic>pare E</italic>.</p>
    <p><italic>S</italic>. Typhi and Paratyphi A with decreased susceptibility to fluoroquinolones emerged on the Indian subcontinent, Southeast Asia, and Central Asia in the mid-1990s (<xref ref-type="bibr" rid="R2"><italic>2</italic></xref>&#x2013;<xref ref-type="bibr" rid="R5"><italic>5</italic></xref>). On disk diffusion testing, these strains were NA-resistant, and susceptible to ofloxacin or ciprofloxacin; however, the MICs of ciprofloxacin increased to 0.25&#x2013;4 &#x3BC;g/mL, 10- to 100-fold higher than the usual NA&#x2013;susceptible strains (<xref ref-type="bibr" rid="R5"><italic>5</italic></xref>,<xref ref-type="bibr" rid="R8"><italic>8</italic></xref>,<xref ref-type="bibr" rid="R9"><italic>9</italic></xref>). NA-resistant strains of <italic>S</italic>. Typhi have 1 point mutation at the target site of quinolones, DNA gyrase, in the quinolone resistance&#x2013;determining region of <italic>gyrA</italic>, either at codon 83 or codon 87 (<xref ref-type="bibr" rid="R2"><italic>2</italic></xref>,<xref ref-type="bibr" rid="R3"><italic>3</italic></xref>). Several epidemics of typhoid and paratyphoid fever caused by NA-resistant strains with clinical failure of quinolone treatment have been reported (<xref ref-type="bibr" rid="R4"><italic>4</italic></xref>,<xref ref-type="bibr" rid="R5"><italic>5</italic></xref>).</p>
    <p>An experimental attempt had been previously made to induce the production of strains with high-level fluoroquinolone resistance by culturing strains of <italic>S</italic>. Typhi and Paratyphi A in ciprofloxacin-supplemented medium (<xref ref-type="bibr" rid="R7"><italic>7</italic></xref>). One of these in vitro&#x2013;induced, high-level resistant strains of <italic>S</italic>. Paratyphi A had triple mutations in the <italic>gyrA</italic> gene at codons 83 and 87 and in the <italic>parC</italic> gene at codon 84, which are the same triple mutations as those seen in the current in vivo case.</p>
    <p>Full fluoroquinolone resistance has already emerged in the community in nontyphoid <italic>Salmonella</italic> species. In a clinical isolate of <italic>S. enterica</italic> serovar Typhimurium, the MIC of ciprofloxacin was 32 &#xB5;g/mL, and mutations in both <italic>gyrA</italic> and <italic>gyrB</italic> were noted (<xref ref-type="bibr" rid="R10"><italic>10</italic></xref>).</p>
    <p>Our findings strongly suggest that high-level quinolone resistance was induced through the long-term carrier state of <italic>S</italic>. Paratyphi A under selective pressure of frequent quinolone administration. The resistance is associated with the 2 mutation sites in <italic>gyrA</italic> and 1 site in <italic>parC</italic>, and multiple point mutations are likely related to the acquisition of full resistance. Physicians should be aware of the emergence of <italic>S</italic>. Typhi and Paratyphi A, as well as nontyphoid <italic>Salmonella</italic> species, which are highly quinolone-resistant.</p>
  </body>
  <back>
    <fn-group>
      <fn fn-type="citation">
        <p><italic>Suggested citation for this article</italic>: Adachi T, Sagara H, Hirose K, Watanabe H. Fluoroquinolone-resistant <italic>Salmonella</italic> paratyphi A [letter]. Emerg Infect Dis [serial on the Internet]. 2005 Jan [<italic>date cited</italic>]. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3201/eid1101.040145">http://dx.doi.org/10.3201/eid1101.040145</ext-link></p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Rowe</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Threlfall</surname>
<given-names>EJ</given-names></string-name>, <string-name><surname>Ward</surname>
<given-names>LR</given-names></string-name>
<article-title>Spread of multiresistant <italic>Salmonella typhi.</italic></article-title>
<source>Lancet</source>. <year>1990</year>;<volume>336</volume>:<fpage>1065</fpage>
<pub-id pub-id-type="doi">10.1016/0140-6736(90)92532-M</pub-id><pub-id pub-id-type="pmid">1977034</pub-id><pub-id pub-id-type="pmid">1977034</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Brown</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Shanahan</surname>
<given-names>PM</given-names></string-name>, <string-name><surname>Jesudason</surname>
<given-names>MV</given-names></string-name>, <string-name><surname>Thomson</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Amyes</surname>
<given-names>SG</given-names></string-name>
<article-title>Mutations responsible for reduced susceptibility to 4-quinolones in clinical isolates of multi-resistant <italic>Salmonella typhi</italic> in India.</article-title>
<source>J Antimicrob Chemother</source>. <year>1996</year>;<volume>37</volume>:<fpage>891</fpage>&#x2013;<lpage>900</lpage>
<pub-id pub-id-type="doi">10.1093/jac/37.5.891</pub-id><pub-id pub-id-type="pmid">8737139</pub-id><pub-id pub-id-type="pmid">8737139</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Wain</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Hoa</surname>
<given-names>NTT</given-names></string-name>, <string-name><surname>Chinh</surname>
<given-names>NT</given-names></string-name>, <string-name><surname>Vinh</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Everett</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Diep</surname>
<given-names>TS</given-names></string-name>, <etal/>
<article-title>Quinolone-resistant <italic>Salmonella typhi</italic> in Viet Nam: molecular basis of resistance and clinical response to treatment.</article-title>
<source>Clin Infect Dis</source>. <year>1997</year>;<volume>25</volume>:<fpage>1404</fpage>&#x2013;<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1086/516128</pub-id><pub-id pub-id-type="pmid">9431387</pub-id><pub-id pub-id-type="pmid">9431387</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Murdoch</surname>
<given-names>DA</given-names></string-name>, <string-name><surname>Banatvala</surname>
<given-names>NA</given-names></string-name>, <string-name><surname>Bone</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Shiosmatulloev</surname>
<given-names>BI</given-names></string-name>, <string-name><surname>Ward</surname>
<given-names>LR</given-names></string-name>, <string-name><surname>Threlfall</surname>
<given-names>EJ</given-names></string-name>
<article-title>Epidemic ciprofloxacin-resistant <italic>Salmonella typhi</italic> in Tajikistan.</article-title>
<source>Lancet</source>. <year>1998</year>;<volume>351</volume>:<fpage>339</fpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(05)78338-0</pub-id><pub-id pub-id-type="pmid">9652619</pub-id><pub-id pub-id-type="pmid">9652619</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Chandel</surname>
<given-names>DS</given-names></string-name>, <string-name><surname>Chaudhry</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Dhawan</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Pandey</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Dey</surname>
<given-names>AB</given-names></string-name>
<article-title>Drug-resistant <italic>Salmonella enterica</italic> serotype Paratyphi A in India.</article-title>
<source>Emerg Infect Dis</source>. <year>2000</year>;<volume>6</volume>:<fpage>420</fpage>&#x2013;<lpage>1</lpage>
<pub-id pub-id-type="doi">10.3201/eid0604.000420</pub-id><pub-id pub-id-type="pmid">10905982</pub-id><pub-id pub-id-type="pmid">10905982</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Giraud</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Brisabois</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Martel</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Chaslus-Dancla</surname>
<given-names>E</given-names></string-name>
<article-title>Comparative studies of mutations in animal isolates and experimental in vitro- and in vivo- selected mutants of <italic>Salmonella</italic> spp. suggest a counterselection of highly fluororquinolone-resistant strains in the field.</article-title>
<source>Antimicrob Agents Chemother</source>. <year>1999</year>;<volume>43</volume>:<fpage>2131</fpage>&#x2013;<lpage>7</lpage><pub-id pub-id-type="pmid">10471553</pub-id><pub-id pub-id-type="pmid">10471553</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Hirose</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Hashimoto</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Tamura</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Kawamura</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Ezaki</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Sagara</surname>
<given-names>H</given-names></string-name>, <etal/>
<article-title>DNA sequence analysis of DNA gyrase and DNA topoisomerase IV quinolone resistance&#x2013;determining regions of <italic>Salmonella enterica</italic> serovar Typhi and serovar Paratyphi A.</article-title>
<source>Antimicrob Agents Chemother</source>. <year>2002</year>;<volume>46</volume>:<fpage>3249</fpage>&#x2013;<lpage>52</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.46.10.3249-3252.2002</pub-id><pub-id pub-id-type="pmid">12234852</pub-id><pub-id pub-id-type="pmid">12234852</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Atkins</surname>
<given-names>BL</given-names></string-name>, <string-name><surname>Gottlieb</surname>
<given-names>T</given-names></string-name>
<article-title>Emerging drug resistance and vaccination for typhoid fever</article-title>
<comment>[letter]</comment>
<source>JAMA</source>. <year>1998</year>;<volume>279</volume>:<fpage>579</fpage>&#x2013;<lpage>80</lpage>
<pub-id pub-id-type="doi">10.1001/jama.279.8.579</pub-id><pub-id pub-id-type="pmid">9486743</pub-id><pub-id pub-id-type="pmid">9486743</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Threlfall</surname>
<given-names>EJ</given-names></string-name>, <string-name><surname>Skinner</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Ward</surname>
<given-names>LR</given-names></string-name>
<article-title>Detection of decreased in vitro susceptibility to ciprofloxacin in <italic>Salmonella enterica</italic> serotypes Typhi and Paratyphi A.</article-title>
<source>J Antimicrob Chemother</source>. <year>2001</year>;<volume>48</volume>:<fpage>740</fpage>&#x2013;<lpage>1</lpage>
<pub-id pub-id-type="doi">10.1093/jac/48.5.740</pub-id><pub-id pub-id-type="pmid">11679569</pub-id><pub-id pub-id-type="pmid">11679569</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Heisig</surname>
<given-names>P</given-names></string-name>
<article-title>High-level fluoroquinolone resistance in a <italic>Salmonella typhimurium</italic> isolate due to alterations in both <italic>gyrA</italic> and <italic>gyrB</italic> genes.</article-title>
<source>J Antimicrob Chemother</source>. <year>1993</year>;<volume>32</volume>:<fpage>367</fpage>&#x2013;<lpage>77</lpage>
<pub-id pub-id-type="doi">10.1093/jac/32.3.367</pub-id><pub-id pub-id-type="pmid">8262859</pub-id><pub-id pub-id-type="pmid">8262859</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
